CSIMarket Company Name, Ticker, Competitors, else..
 
Galecto Inc   (NASDAQ: GLTO)
Other Ticker:  
 
 
Price: $2.9000 $0.05 1.754%
Day's High: $3.2248 Week Perf: 12.84 %
Day's Low: $ 2.81 30 Day Perf: -52.46 %
Volume (M): 42 52 Wk High: $ 18.50
Volume (M$): $ 121 52 Wk Avg: $9.08
Open: $2.88 52 Wk Low: $2.01



 Market Capitalization (Millions $) 3
 Shares Outstanding (Millions) 1
 Employees 10
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -21
 Cash Flow (TTM) (Millions $) 4
 Capital Exp. (TTM) (Millions $) 0

Galecto Inc
Galecto Inc is a biotechnology company that focuses on developing novel therapies to treat fibrosis, cancer, and other related diseases. The company specializes in regulating galectin proteins, which play important roles in various biological processes, including inflammation, tissue remodeling, and cell proliferation. Galecto's pipeline includes potential treatments for conditions such as idiopathic pulmonary fibrosis, liver fibrosis, and pancreatic cancer. The company is known for its expertise in galectin biology and innovative drug discovery approaches, aiming to provide effective therapies for patients with unmet medical needs.


   Company Address: 75 State Street Boston 2109 MA
   Company Phone Number: 70 70 52 10   Stock Exchange / Ticker: NASDAQ GLTO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV        9.33% 
BMY   -2.13%    
JNJ   -1.49%    
MRK        6.28% 
PFE        3.99% 
SNY        3.55% 
• View Complete Report
   



Merger and Acquisition

Galecto Inc. Refocuses Pipeline on Oncology and Liver Disease with Strategic Acquisition, Poised for Growth

Published Mon, Oct 7 2024 12:46 PM UTC

Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology firm, recently made...
Shares

Galecto Implements Reverse Stock Split to Ensure Nasdaq Listing Compliance

Published Wed, Aug 28 2024 1:00 PM UTC


Galecto, Inc., a clinical-stage biotechnology company specializing in cancer and fibrosis treatments, recently announced its decision to implement a 1-for-25 Reverse Stock Split of its common stock. This move, approved by shareholders during the Annual Meeting of Stockholders in June, aims to bring the company into compliance with the minimum bid price requirement for ...
Clinical Study

Evolving Cancer Therapy: Galecto Introduces GB1211 in a Pioneering Investigator-Initiated, NCI-Supported Phase 2 Trial

Published Wed, May 1 2024 8:01 PM UTC

Galecto, a biotechnology company leading the way in novel galectin inhibitors, has recent advanced strides in their ongoing pursuit of innovative approaches for the treatment of metastatic melanoma and head and neck squamous cell carcinoma. Now, they have announced the dosing of their first patient in a trailblazing Phase 2 trial, which involves an investigator-initiated exp...
Clinical Study

MYLOX-1 Trial: GB2064 Monotherapy Proves Effective in Reducing Bone Marrow Fibrosis in Myelofibrosis Patients, Validating LOXL2 as a Promising Clinical Target

Published Thu, Dec 21 2023 9:05 PM UTC

In a groundbreaking clinical trial known as MYLOX-1, promising results have emerged, demonstrating a significant reduction in fibrosis of the bone marrow in patients with myelofibrosis. The trial evaluated the efficacy of GB2064 monotherapy, which successfully led to a 1-grade reduction in collagen fibrosis in six out of ten evaluable patients. These remarkable findings have...
Galecto Inc

Galecto Inc Unveils Impressive Q3 Earnings; Investors Eager to Uncover the Company's Future Performance

Galecto Inc Shows Promising Improvement in Q3 Earnings; Future Performance Under Spotlight
Investors eagerly await the financial performance of Galecto Inc, a prominent player in the healthcare sector, as the company gears up to release its next financial report on March 8, 2024. While stockholders have not factored in some adjustments in the business during the July to September 30, 2023 earnings season, they have noted GLTO's operating deficit, which stood at -$8.583 million during the same period. However, the emerging growth entity has caught investors' attention by demonstrating improved business efficiency compared to the previous fiscal year.
Galecto Inc's journey from an operating deficit of -$13.622 million in the fiscal period ending September 30, 2022, to a positive surprise of -$8.136 million in the third quarter of 2022 echoes the strides the company has made. This reduction in losses positions the firm as a potential frontrunner in the healthcare sector. Investors remain optimistic about Galecto Inc's path to becoming a successful leader in the industry.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com